VST-BIO Announces Successful Preclinical Trials in Ischemic Stroke

VST-Bio’s Collaborators Present Preclinical Trial Results at the American Heart Association International Stroke Conference in Dallas.

Excerpt from the Press Release:

SAN DIEGO, Feb. 10, 2023 /PRNewswire/ — VST-Bio Corp. a leader in the development of innovative biologics to treat acute and chronic cardiovascular disease, presented data from a recent large animal study performed by VST-Bio and Yale University demonstrating that a single iv bolus of VST-002 led to meaningful reduction in brain damage and improved function in an advanced model of ischemic stroke.

Dr. Federico Corti, from the Cardiovascular Research Center of Yale University, presented data which showed that a single bolus of humanized anti-Syndecan 2 antibody (VST-002), led to 60% reduction of stroke damage as visualized by magnetic resonance imaging, with all measures being statistically significant over control animals. Furthermore, the treatment was safe with no observed toxicities. The study was performed by an independent CRO, blinded to treatment assignment.

VST-Bio Chief Executive Officer Eric Duckers, MD PhD, said, “The VST-002 human antibody therapy is being initially developed to treat ischemic stroke patients (Cerebrovascular Accident – CVA) who present late at the medical centers, when conventional therapy is no longer effective. The current standard-of-care is thrombolytic therapy to resolve blood clots, but unfortunately is only effective when given within the first few hours of stroke, leaving 90% of all patients ineligible or non-responsive to conventional treatment. VST-002 may offer an alternative path to preserve brain function and improve recovery after ischemic stroke”.

Click the button below to read the entire Press Release:

Continue Reading The Press Release